A pharmaceutical composition or a cosmetic composition for treating hair loss, or promoting hair growth is described. The composition according to the present invention exhibits an excellent effect of treating hair loss and promoting hair growth, and can be safely used regardless of sex and age.

The present invention relates to a composition for surface modification. The composition for surface modification according to the present invention contains a particular carbodiimide-based compound, thus forms a covalent bond without damaging skin, hair, or fabric, and semipermanently provides desired skin or hair surface modification effects or fabric care effects.

The purpose of the present invention is to provide microorganisms which efficiently produce nicotinamide riboside, and microorganisms which can efficiently produce both nicotinamide mononucleotide and nicotinamide riboside. Nicotinamide mononucleotide and nicotinamide riboside can be produced by culturing lactic acid bacteria belonging to the genus Fructobacillus.

Cosmetic compositions are widely used to obtain certain benefits like e.g. anti-aging, skin lightening and moisturizing effect. These benefits are delivered by benefit agents (actives) like e.g. anti-oxidants, hyaluronic acid and resorcinol, pheynylethyl resorcinol and 4-alkyl substituted resorcinol. However, these actives have a certain shelf life beyond which they tend to degrade in terms of chemical activity and/or their color stability. The present invention discloses a novel process to prepare cosmetic compositions that improved color stability of resorcinol, pheynylethyl resorcinol and 4-alkyl substituted resorcinol and compositions comprising such actives when prepared as per said process.

Described herein are compositions for delaying onset or delaying progression of frailty, reversing aging phenotype, extending healthspan, compressing morbidity, increasing lifespan and reducing formation of senescent cells.

Keratin protein cosmetic compositions are provided that include at least one keratin protein derived from human hair and a base cosmetic solution. Methods of treatment are also provided.

Hair treatment compositions are provided that include alpha keratin and gamma keratin proteins derived from human hair, at least one biomimetic signal peptide, and red clover extract. Methods of treatment are also provided.

Various embodiments provide an antimicrobial composition comprising: a safe and effective amount of benzoic acid analog or analogs; a safe and effective amount of a buffer system of weak organic acids buffer with the negative log of the acid dissociation constant, pKa, between about 3.2 and 4.9; and a dermatologically acceptable carrier for the benzoic acid analogs and weak organic acid buffers, wherein the antimicrobial composition has a pH from about 3.2 to 4.9. In some embodiments, the antimicrobial composition comprises a safe and effective amount of an antimicrobial metal ion salt, a preferred salt being copper gluconate, at a level and pH that does not precipitate with the weak acid buffers.

A skin cleansing device has a base body and a removable cleansing head. The base body houses a vacuum pump and has a mount for connecting to the removable cleansing head. The mount has an opening into the base body and a support surface. The removable cleansing head has a collection portion and a mounting portion. The collection portion defines an inlet and an internal cavity. The mounting portion has a stem defining a channel fluidly connected to the internal cavity. The cleansing head is removably connectable to the base body with the stem being configured to be received in the opening of the mount. The vacuum pump is configured to generate a fluid flow through the internal cavity and the channel into the base body such that a suction force is generated at the inlet.

Provided are pharmaceutical compositions for skin lightening, which are particularly useful in treating skin hyperpigmentation, together with methods for their use. The compositions comprise glutathione conjugated to a peptide having a sequence comprising PKEK (SEQ ID NO: 1) and cysteamine or a pharmaceutical salt thereof.